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Machado-Joseph disease or spinocerebellar ataxia type 3, the most common dominantly-inherited spinocerebellar ataxia, results
from translation of the polyglutamine-expanded and aggregation prone ataxin 3 protein. Clinical manifestations include cere-
bellar ataxia and pyramidal signs and there is no therapy to delay disease progression. Beclin 1, an autophagy-related protein
and essential gene for cell survival, is decreased in several neurodegenerative disorders. This study aimed at evaluating if
lentiviral-mediated beclin 1 overexpression would rescue motor and neuropathological impairments when administered to pre-
and post-symptomatic lentiviral-based and transgenic mouse models of Machado-Joseph disease. Beclin 1-mediated significant
improvements in motor coordination, balance and gait with beclin 1-treated mice equilibrating longer periods in the Rotarod and
presenting longer and narrower footprints. Furthermore, in agreement with the improvements observed in motor function beclin
1 overexpression prevented neuronal dysfunction and neurodegeneration, decreasing formation of polyglutamine-expanded
aggregates, preserving Purkinje cell arborization and immunoreactivity for neuronal markers. These data show that overexpres-
sion of beclin 1 in the mouse cerebellum is able to rescue and hinder the progression of motor deficits when administered to
pre- and post-symptomatic stages of the disease.
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Introduction
The autosomal dominant spinocerebellar ataxias (SCAs) are a com-
plex group of neurodegenerative disorders that comprise 28 dif-
ferent genetic loci and are characterized by progressive cerebellar
ataxia of gait and limbs along with other variable symptoms.
Among the SCAs, six are known to be polyglutamine diseases
(SCA1–3, SCA6–7 and SCA17) (Duenas et al., 2006; Carlson
et al., 2009).
Machado–Joseph disease, also known as spinocerebellar ataxia
type 3 (SCA3) is the most common autosomal dominant SCA and
one of the most common polyglutamine diseases worldwide
(Schols et al., 2004). The disease is caused by a genetic mutation
involving over-repetition of the trinucleotide CAG in the MJD1/
ATXN3 gene, which translates into an expanded polyglutamine
tract within the ataxin 3 protein (Kawaguchi et al., 1994). This
protein adopts an abnormal folding and has an increased propen-
sity to aggregate (Paulson et al., 1997). The expanded polygluta-
mine tract is shared among the polyglutamine diseases, which
accounts for the clinical and neuropathological similarities
observed in these diseases (Bauer and Nukina, 2009). Machado–
Joseph disease is a multisystem neurodegenerative disorder char-
acterized by a wide range of clinical manifestations that include:
limb and gait cerebellar ataxia; pyramidal syndrome; peripheral
neuropathy and extra-pyramidal signs including dystonia, rigidity
and/or bradykynesia, among others (Rosenberg, 1992; Sudarsky
and Coutinho, 1995). The clinical manifestations appear late in life
and there is growing evidence that to this may contribute a pro-
gressive failure of protein degradation systems (Cuervo, 2004).
Beclin 1 was among the first mammalian autophagy effectors to
be identified (Liang et al 1998). It is a key protein of the autop-
hagy clearance pathway, whose activity is inhibited by binding of
Bcl-2 homologs to its BH3 domain. In mammalian cells, beclin 1
interacts with the class III PI3K to activate the nucleation step of
autophagy, also playing a role in the fusion of autophagosomes to
lysosomes (Itakura et al., 2008; Sun et al., 2008; Matsunaga
et al., 2009; Zhong et al., 2009). Beclin 1 appears to play a gen-
eral role in cell survival. In mice, homozygous deletions
(Becn1/) lead to death at an early embryonic stage (Qu
et al., 2003; Yue et al., 2003) while heterozygous deletions
(Becn1+/) lead to an increased frequency of spontaneous lymph-
omas and carcinomas (Qu et al., 2003; Yue et al., 2003) as well as
alterations in neuronal autophagy and neuronal function (Pickford
et al., 2008). On the contrary, overexpression of beclin 1 in the
brain of adult mice has been shown to protect neurons from
apoptosis induced by Sindbis virus infection (Liang et al., 1998)
as well as from accumulation of misfolded proteins (Pickford et al.,
2008; Jaeger et al., 2010). In previous work, we and others have
reported that levels of beclin 1 were decreased upon ageing,
Alzheimer’s disease, Huntington’s disease and Machado–Joseph
disease (Shibata et al., 2006; Pickford et al., 2008; Nascimento-
Ferreira et al., 2011), wheras beclin 1 overexpression increased the
autophagic clearance of misfolded amyloid-b (Pickford et al.,
2008; Jaeger et al., 2010), alpha-synuclein (Spencer et al.,
2009) and ataxin 3 protein (Nascimento-Ferreira et al., 2011)
and at the same time promoted neuroprotection. Nevertheless, it
has not yet been proved if these neuroprotective effects of beclin
1 are translated into motor improvements, which would be a
major asset to these highly motor-incapacitating diseases.
From a translational perspective it is important to investigate if
beclin 1 overexpression per se may improve neuropathology and
motor behaviour in mice already severely affected by the move-
ment disorder, an outcome that is relevant for polyglutamine dis-
eases and SCAs in general. In fact, several studies have recently
shown that some drugs used in cancer therapy, such as imatinib
(Can et al., 2011), lapatinib (Huang et al., 2011) and sunitinib
(Zhao et al., 2010), can upregulate beclin 1, opening a new thera-
peutic window for these drugs and hopefully, for several neuro-
degenerative diseases.
Therefore, in this work we aimed at evaluating whether beclin 1
would be able to improve motor and neuropathological deficits
when administered to two different mouse models: a lentiviral-
based model of Machado–Joseph disease presymptomatic at the
time of initiation of beclin 1 expression, and a transgenic mouse
model expressing a truncated fragment of mutant ataxin 3
(Torashima et al., 2008), symptomatic and with cerebellar atrophy
since the beginning of the study.
Beclin 1 was able to hamper the development of motor deficits
and neuropathology when administered to the lentiviral mouse
model, improving motor coordination, balance, gait and expres-
sion of neuronal markers to a level similar to wild-type mice. In
addition, beclin 1 was also able to mediate improvements in the
motor function as well as a decrease in the cerebellar atrophy
when administered after onset of the pathology to transgenic
mice resembling a late and severe phenotype of cerebellar
ataxia. This study shows that beclin 1 overexpression hinders the
progression of motor and neuropathological abnormalities when
administered to pre- and postsymptomatic stages of Machado-
Joseph disease, an observation not only relevant to polyglutamine
diseases and cerebellar ataxias but also to other neurodegenerative
diseases.
Materials and methods
Lentiviral vectors
Viral vectors encoding for GFP (Regulier et al., 2002), human beclin-1,
EGFP-LC3 (Nascimento-Ferreira et al., 2011) and human full-length
mutant ataxin 3 with 72 glutamines (Atx3Q72) (Alves et al., 2008),
were produced in human embryonic kidney (HEK) 293T cells using a
four-plasmid system described previously (de Almeida et al., 2001,
2002). Viral stocks were stored at 80C until use.
Primary cerebellar cell culture
The primary cerebellar cell culture was isolated from transgenic Q69
(confirmed by genotyping) within 6–7 days after birth. Cells were
cultured with a density of 500 000 cells/ml in Neurobasal medium
(Gibco, Life Technologies), supplemented with L-glutamine (Sigma)
(0.5 mM), gentamicin (Gibco, Life Technologies) (50 mg/ml), B-27 sup-
plement (Gibco, Life Technologies), and potassium chloride (Sigma)
(2 M). Cells were plated and maintained in multiwells previously
coated with poly-L-lysine (Sigma), at 37C in 5% CO2/air atmosphere.
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Cerebellar cell culture infection
For the infection of cerebellar cells culture, the medium was replaced
with 400ml of new complete medium and 1.6 ml of hexadimethrine
bromide (Sigma-Aldrich) (8 mg/ml) and the corresponding lentivirus
added (10 ng/100 000 cells) according to the condition (beclin 1 or
GFP as control). The multiwells were then incubated at 37C in 5%
CO2/air atmosphere, and after 6 h of infection, 600ml of new fresh
medium (complete) was added to the wells. At 2 weeks post-infection
cells were lysed for western blotting analysis.
Neuroblastoma cell culture
Mouse neuroblastoma cell line (Neuro-2A cells) obtained from the
American Type Culture Collection cell biology bank (CCL-131) were
incubated in Dulbecco’s modified Eagle’s medium supplemented with
10% foetal bovine serum, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Gibco) (complete medium) at 37C in 5% air atmosphere.
Neuroblastoma cell cultures infection
and drug treatment
Cells were plated and infected with lentiviral particles expressing
enhanced green fluorescent protein-light chain 3 (EGFP) with or with-
out beclin-1 lentiviral vector at the ratio of 10 ng of p24 antigen/105
cells. At 2 weeks post-infection, cells were treated with rapamycin
(0.2 mM) for 6 h or control (dimethyl sulphoxide) in the presence or
absence of chloroquine (100 mM) for 6 h. The cells were then fixed for
microscopy and lysed for western blot.
Neuroblastoma cell cultures imaging
and quantification
Cells expressing EGFP-LC3 alone, co-expressing beclin 1 or treated
with rapamycin were analysed by confocal microscopy (2 weeks
after infection). Chloroquine, a drug known to raise the lysosomal
pH, leading to inhibition of both fusion of autophagosomes with lyso-
somes and lysosomal protein degradation (Shintani and Klionsky,
2004) was used to allow autophagosome accumulation and quantifi-
cation. LC3 puncta and size were quantified using the ‘analyse par-
ticles’ function of the ImageJ software after thresholding of images
with size settings from 0.2–10 pixel2 and a circularity of 0–1. At
least 15 cells were analysed for each condition. Values are expressed
as mean  SEM of threee independent experiments.
Protein extraction and western blotting
Brains and cells were lysed in RIPA-buffer solution (50 mM Tris HCl pH
8, 150 nM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing protease inhibitors (Roche diagnostics) followed by a 4 s
ultra-sound chase (1 pulse/s). Protein concentration was determined
with the Bradford protein assay (Bio-Rad). Sixty micrograms of protein
extract were resolved in SDS-polyacrylamide gels (12%). The proteins
were transferred onto PVDF membrane (GE Healthcare) according to
standard protocols. The membranes were blocked by incubation in 5%
non-fat milk powder in 0.1% Tween 20 in Tris buffered saline (TBS-T)
for 1 h at room temperature, and were then incubated overnight at
4C with mouse monoclonal anti-beclin 1 (BD Biosciences; 1:1000),
mouse monoclonal anti-b-actin (Sigma; 1:5000), rabbit anti-LC3 (Cell
Signaling; 1:1000), mouse anti--tubulin (Sigma; 1:5000) antibodies.
Blots were washed three times in TBS-T, for 15 min each, and
incubated with the secondary antibody goat anti-mouse or anti-
rabbit (1:10 000; Vector Laboratories) for 2 h at room temperature.
Blots were washed three times in TBS-T, for 15 min each and the
bands were visualized with Enhanced Chemifluorescent substrate
(ECF) (GE Healthcare) and chemifluorescence imaging (Versadoc
Imaging System Model 3000, Bio-Rad). Semi-quantitative analysis
was carried out based on the optical density of scanned membranes
(Quantity One 1-D image analysis software version 4.4; Bio-Rad).
The specific optical density was then normalized with respect to the
amount of b-actin or alpha-tubulin loaded in the corresponding lane of
the same gel.
Flow cytometry analysis
Wild-type mice with 21 days of age were stereotaxically-injected in
the cerebellar cortex with lentiviral vectors encoding EGFP-LC3 (n = 4)
or EGFP-LC3 plus beclin 1 (1:1; n = 3). Two weeks post-injection mice
were sacrificed and transcardiacally perfused with a phosphate buffer
solution. Afterwards, the brain was removed, the cerebellar cortex
isolated and homogenized using a glass dounce homogenizer. The
homogenate solution was then filtered through a 70/40 mm cell strai-
ner into a 50 ml Falcon tube to obtain a single-cell suspension.
Centrifugation at 1200 rpm for 5 min at room temperature was
performed twice to pellet and wash the cells in PBS. The final pellet
was resuspended in 1 ml of PBS to be sequentially analysed by flow
cytometry. Samples were kept on ice until use, and analysis of 100 000
cells per animal was performed on a fluorescence-activated cell-
detector flow cytometer (Becton Dickinson). Data of viable cell
counts was plotted as GFP fluorescence intensity (FL1 channel,
530  30 nm).
In vivo experiments
Transgenic mouse model
Polyglutamine disease transgenic mouse models expressing the N-ter-
minal-truncated ataxin 3 with 69 glutamine repeats and an N-terminal
haemagglutinin epitope driven by Purkinje-cell-specific L7 promoter
(Tg-Q69) were previously described (Torashima et al., 2008; Oue
et al., 2009). A colony of these transgenic mice was established in
the Centre for Neuroscience and Cell Biology of the University of
Coimbra and the line was maintained by backcrossing heterozygous
males with C57BL/6 females. Genotyping was performed by PCR. The
present study used eight heterozygous females and eight heterozygous
males divided in two groups of animals injected with lentiviral vectors
encoding GFP (Tg-Q69 + control; n = 8) and beclin 1 (Tg-Q69 +
beclin 1; n = 8), respectively. The wild-type littermates, 16 males and
14 females were used for control (wild-type, n = 8) and for the lenti-
viral-based Machado–Joseph’s disease model. The behavioural testing
began at 21–25 days of age (P21–25). At this age, transgenic mice
were already phenotypically distinguishable from their wild-type litter-
mates by home-cage behaviour.
Lentiviral Machado–Joseph disease mouse model
Experiments with the lentiviral Machado–Joseph disease mouse model,
previously characterized (Nobrega et al., 2012), involved injection of
a mix of lentiviral vectors (1:1) encoding, in the control group, the
full-length mutant ataxin 3 with 72 glutamine repeats and GFP
(LV-Atx3Q72 + control; n = 8) and in the other group, the full-
length mutant ataxin 3 with 72 glutamine repeats and beclin 1
(LV-Atx3Q72 + beclin 1; n = 8). The behavioural testing began at
21–25 days of age (P21–25). All animals were housed in a
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temperature-controlled room and maintained on a 12 h light/dark
cycle. Food and water were available ad libitum. The experiments
were carried out in accordance with the European Community
Council directive (86/609/EEC) for the care and use of laboratory
animals.
Stereotaxic surgery
Concentrated viral stocks were thawed on ice and resuspended by vor-
texing. Mice were anaesthetized by intraperitoneal injection of a mixture
of ketamine (100 mg/kg) with xylazine (10 mg/kg). Particle content of
lentiviral vectors was matched to 200 000 ng of p24/ml. The animals
received a single injection of 6ml of lentiviral vectors (6ml of beclin 1/
GFP in Tg-Q69 mice; 3 + 3ml of mutant Atx3 + beclin 1/GFP in LV-
Atx3Q72 mice) at a rate of 0.25ml/min by means of an automatic
injector (Stoelting Co.), at the following coordinates: 1.6 mm rostral
to lambda, 0.0 mm midline, and 1.0 mm ventral to the skull surface,
with the mouth bar set at 3.3. After the injection, the syringe needle
was left in place for an additional 5 min to minimize backflow.
Behavioural assessment
Mice were trained on a battery of motor tests starting at 21–25 days
of age (P21–25), before surgery (T0) and performed every 2 weeks
until 10 weeks. All tests were performed in a dark room after 30 min
of acclimatization.
Modified beam test
Motor coordination and balance were assessed by measuring the abil-
ity of mice to hold or walk for 15 s in long wood beams (1 m) of 0.5
and 0.8 mm round diameter or 1 mm of square cross section. The
beams were placed horizontally, 50 cm above a padded surface, with
both ends mounted on a support. The test started with the most dif-
ficult beam (0.5 mm round) and ended with the easiest beam (1 mm
square). The score given to each animal corresponded to the beam in
which they could perform the test.
Rotarod
The Rotarod apparatus (Letica Scientific Instruments) was used to
measure fore and hind limb motor coordination and balance. Each
mouse was placed on the Rotarod at a constant speed (5 rpm) for a
maximum of 5 min, and at an accelerated speed (4 to 40 rpm in 5 min)
for a maximum of 5 min. The latency to fall was recorded. Mice were
allowed to perform four trials for each test and time point, with 15 min
rest between trials. For analysis, the mean latency to fall off the
Rotarod of three to four trials was used.
Footprint test
The footprint test was used to compare the gait of beclin 1 and con-
trol-treated lentiviral and transgenic Machado–Joseph disease mice. To
obtain the footprints, the mice hind- and forefeet were coated with
black and green non-toxic paints, respectively. The animals were then
allowed to walk along a 100-cm long, 10-cm wide runaway (with
15-cm high walls). A fresh sheet of white paper was placed on the
floor of the runaway for each mouse run. The footprint patterns were
analysed for four step parameters (all measured in centimetres). Stride
length was measured as the average distance of forward movement
between each stride. Hind-base width and front-base width were
measured as the average distance between left and right hind foot-
prints, respectively. These values were determined by measuring the
perpendicular distance of a given step to a line connecting its opposite
preceding and proceeding steps. Distance from left or right front foot-
print/hind footprint overlap was used to measure uniformity of step
alternation. When the centre of the hind footprint fell on top of the
centre of the preceding front footprint, a value of zero was recorded.
When the footprints did not overlap, the distance between the centre
of the footprints was recorded. A sequence of six consecutive steps
was chosen for evaluation, excluding footprints made at the beginning
and end of the run where the animal was initiating and finishing
movement, respectively. The same operator made all footprint meas-
urements. The mean value of each set of five to six values was used
for analysis.
Histological processing
Tissue preparation
Animals were killed by sodium pentobarbital overdose, transcardially
perfused with a 4% paraformaldehyde fixative solution (PFA 4%,
Fluka) followed by brain removal. After a cryoprotective incubation
in 25% sucrose, 0.1 M PBS for 48 h, brains were frozen in dry ice
(80C) and 20mm coronal sections were cut at a cryostat-microtome
(Leica CM3050S, Leica Microsystems). Slices throughout the entire
cerebellum were collected in SuperFrost plus microscope slides
(Thermo Fisher Scientific) and stored at 20C before immunohisto-
chemical processing.
Immunohistochemical procedure
The immunohistochemical procedure was initiated with a 30 min dehy-
dration at 37C followed by a 30 min hydration in 0.1 PBS and 1 h
blocking in a 0.3% TritonTM in 0.1 PBS with 10% normal goat serum
both at room temperature. The following primary antibodies diluted in
blocking solution with 0.1% TritonTM were used: mouse monoclonal
anti-ataxin 3 (1H9, Chemicon; 1:5000; overnight, 4C), mouse mono-
clonal anti-haemagglutinin (InvivoGen; 1:1000; overnight, 4C), mouse
monoclonal anti-beclin 1 (BD Biosciences; 1:1000; overnight, 4C),
rabbit polyclonal anti-DARPP-32 (Chemicon; 1:5000, overnight, 4C)
and rabbit polyclonal anti-Calbindin D-28K (Chemicon; 1:1000, over-
night, 4C). Sections were then incubated in secondary antibody,
goat-anti rabbit and/or mouse conjugated to Alexa Fluor 488 or 594
(Invitrogen) for 2 h at room temperature and then mounted in
FluorSaveTM (Calbiochem) with 4’,6’-diamidino-2-phenylindole (DAPI).
Fluorescence images were acquired with a Zeiss Axiovert 200 imaging
microscope or LSM Zeiss microscope for double staining experiments.
In vivo imaging quantification
Quantification of ataxin 3-positive inclusions was performed in the
lentiviral model after performing 1H9 immunohistochemistry and ima-
ging. Six mice/group (n = 6) were used and four coronal sections
spread over the anterior–posterior extent of the cerebellum (inter-sec-
tion distance: 200 - 300 mm) were scanned using a 20 objective on a
Zeiss Axiovert 200 imaging microscope as well as an image acquisition
and analysis software (ImageJ, NIH). For each coronal section and
animal eight fields were acquired. The average number of inclusions
per section of the cerebellum was calculated for each animal.
Quantification of haemagglutinin-tagged ataxin 3-positive inclusions
was performed in the transgenic model after performing haemagglu-
tinin immunohistochemistry and imaging. Five mice/group (n = 5)
were used and four coronal sections spread over the anterior–posterior
extent of the cerebellum (inter-section distance: 200–300mm) were
scanned using a 40 objective on a Zeiss Axiovert 200 imaging micro-
scope as well as an image acquisition and analysis software (ImageJ,
NIH). For each coronal section and animal eight fields were acquired.
The average number of inclusions per 100 cells quantified by DAPI
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staining was calculated for each animal. The quantification of DARPP-32
(now known as PPP1R1B) neuronal expression was performed by scan-
ning four coronal sections spread over the anterior–posterior extent of
the cerebellum expressing the DARPP-32 protein using a 40 objective
on a Zeiss Axiovert 200 imaging microscope. Six mice per group were
used for the lentiviral model (n = 6) and three mice per group (n = 3)
were used for the transgenic model. For each coronal section and animal,
eight fields were acquired using the same exposure. Optical densitom-
etry analysis was performed using ImageJ analysis software. Cerebellar
regions expressing DARPP-32 revealed to have an increased optical
density value when compared to regions not expressing the DARPP-32
protein. Values are represented as the mean value of DARPP-32 optical
density per section (in arbitrary units). The quantification of calbindin
neuronal expression was performed by scanning four coronal sections
spread over the anterior–posterior extent of the cerebellum expressing
the calbindin protein using a 20 objective on a Zeiss Axiovert 200
imaging microscope. Four mice/group were used for both models
(n = 4). For each coronal section and animal, eight fields were acquired
using the same exposure. Optical densitometry analysis was performed
using ImageJ analysis software. Cerebellar regions expressing calbindin
were revealed to have an increased optical density value when
compared to regions not expressing this protein. Values are represented
as the mean value of calbindin optical density per section (in arbitrary
units).The quantification of the size of the molecular layer was performed
by measuring the width of the molecular layer starting at the Purkinje
cells. For that purpose three coronal sections per animal stained with
calbindin markers were scanned using a 20 objective on a Zeiss
Axiovert 200 imaging microscope. Measurements were performed in
triplicate and results converted in micrometres by means of analysis soft-
ware (ImageJ, NIH).
Cresyl violet histological staining
Coronal and sagittal brain sections were stained with cresyl violet dye
for 2 min, differentiated in acetate buffer pH 3.8 (2.72% sodium acet-
ate and 1.2% acetic acid; 1:4 v/v), dehydrated by passing twice
through ethanol and toluene solutions, and mounted with Eukitt
(O. Kindler GmbH & CO).
Quantification of the number of Purkinje cells was performed by
scanning four coronal sections spread over the anterior–posterior
extent of the cerebellum, using a 20 objective on a Zeiss Axiovert
200 imaging microscope and an image analysis software (ImageJ, NIH).
For each coronal section and mice (n = 4/group) six fields were acquired
and Purkinje cells counted in a defined region. Values are represented as
the mean number of Purkinje cells per 100mm  SEM.
Statistical analysis
Differences among groups over time were evaluated by two-way
ANOVA followed by Bonferroni’s post hoc test; differences between
three groups at the same time point by one-way ANOVA followed by
Bonferroni’s post hoc test; and comparisons between two groups by
unpaired Student’s t-test, always using the GraphPad Prism software.
Results
Beclin 1 activates autophagy
We previously showed that beclin 1 stimulates autophagic flux
and clearance of mutant ataxin 3 when administered to in vitro
and in vivo Machado–Joseph disease models (Nascimento-Ferreira
et al., 2011). Here we investigated beclin 1 ability to increase
autophagy as compared with rapamycin, a drug commonly used
as an autophagy inducer in a non-Machado–Joseph disease model
context. For that we infected Neuro-2a cells with a vector encod-
ing EGFP-LC3 with or without beclin 1 vector, treated later with
rapamycin or control (dimethyl sulphoxide) in the presence or ab-
sence of chloroquine (Fig. 1A–I). Beclin 1 significantly increased
EGFP-LC3 puncta formation, an effect that is apparent upon add-
ition of the lysosomotropic agent chloroquine (Fig. 1F and G;
n = 3, P50.001). Interestingly, beclin 1 mediated a robust in-
crease in LC3 puncta, which was superior to that observed with
rapamycin (Fig. 1E and G; n = 3, P5 0.01). To confirm beclin 1-
mediated effect as an autophagy enhancer, two further sets of
experiments were performed in vitro and in vivo: we measured
LC3-II levels in Neuro-2A by western blot (Fig. 1H and I) and
EGFP-LC3 levels in lentiviral-injected mice by flow cytometry
(Fig. 1J and K; n = 3–4, P50.01). In both experiments beclin 1
increased autophagic flux, as highlighted by the increased accu-
mulation of autophagosomes upon chloroquine addition (Fig. 1 H
and I) and increased autophagosomal degradation of EGFP-LC3
visualized by flow cytometry (Fig. 1K, n = 3–4, P5 0.01), a tech-
nique previously characterized for this purpose (Nascimento-
Ferreira et al., 2011).
Beclin 1 improves balance and motor
coordination deficits in lentiviral–based
and transgenic mouse models of
polyglutamine disease
Subsequently, we evaluated if beclin 1 was able to (i) hamper the
development of motor symptoms when administered to a pre-
symptomatic lentiviral-based Machado–Joseph disease mouse
model (Fig. 2A, C, E, G, I and K); and (ii) rescue the motor im-
pairments in a post-symptomatic transgenic mouse model of
Machado-Joseph disease and polyglutamine ataxias (Fig. 2B, D,
F, H, J and L). In the lentiviral-based Machado–Joseph disease
mouse model (LV-Atx3Q72; Fig. 2A, C, E, G, I and K), lentiviral
vectors encoding beclin 1 or Green Fluorescent Protein (GFP, con-
trol) were co-injected with vectors encoding the full-length mutant
ataxin 3 with 72 glutamines (Atx3Q72) in the cerebellum of wild-
type mice at 21 days of age (P21). On the other hand, in the
transgenic mouse model (Tg-Q69; Fig. 2B, D, F, H, J and L),
lentiviral vectors encoding beclin 1 or GFP (control) were admini-
strated to mice already expressing a truncated fragment of mutant
ataxin 3 with 69 glutamines (Q69) (Torashima et al., 2008).
Importantly, since the beginning of the study (P21) these mice
already presented an important cerebellar atrophy (Fig. 2D and
F), in particular of the molecular layer of the cerebellum
(Fig. 2F), compared with age-matched wild-type mice used to
generate the LV-Atx3Q72 (Fig. 2C and E). A single injection of
beclin 1 or GFP led to an extensive transduction of the cerebellar
cortex (Fig. 2G and H). A significant increase in beclin 1 levels was
also observed in beclin 1-injected LVAtx3Q72 mice (Fig. 2I–K;
n = 3; 1.24  0.084 versus 0.86  0.11 in control, P = 0.0477)
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and P7 cerebellar cultures of transgenic mice (Fig. 2J-L; n = 3;
1.67  0.045 versus 0.88  0.10 in control, P = 0.0021).
Behavioural testing was initiated 1 day before injection of the
lentiviral vectors (Fig. 3; T0) and was performed until 10 weeks
post-injection (Fig. 3; T10). In the accelerated Rotarod (acceler-
ation from 4 to 40 rotations per min in 5 min), beclin 1-treated
LV-Atx3Q72 mice (LV-Atx3Q72 + beclin 1) were rescued from
the impairment in balance and motor coordination of GFP-treated
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Figure 1 Beclin 1 activates autophagic flux. (A–G) Confocal imaging and quantification. Neuroblastoma cells (Neuro-2A) expressing
EGFP-LC3 alone (A and D), co-expressing beclin 1 (C and F) or treated with rapamycin (B and E) were analysed by confocal microscopy in
the absence (A–C) or presence of chloroquine (D–F). Quantification of EGFP-LC3-positive puncta (G) confirmed that both rapamycin and
beclin 1 increased the number of autophagosomes, an effect particularly apparent in the presence of chloroquine. Values are expressed as
mean  SEM (n = 3; *P50.05, **P5 0.01, ***P50.001). (H–I) Western blot analysis. Neuro-2A expressing beclin 1 (Bec), control
(Control) or rapamycin (Rap) in the absence (left lanes) or presence of chloroquine (right lanes) were analysed for endogenous LC3-I and
LC3-II levels by western blot (H). Tubulin was used as loading control. Quantification was performed by optical densitometry analysis (I).
Each LC3-II levels were normalized according to the tubulin band. Results are expressed as ratio LC3-II/ tubulin. Values are expressed as
mean  SEM (n = 3; *P50.05). (J and K) Flow cytometry. EGFP-LC3-injected mice expressing this vector alone (n = 4) or co-expressing
beclin 1 (n = 3) were analysed by flow cytometry 2 weeks after injection. Results are expressed as the geometric mean of the fluorescent
signal. Values are expressed as mean  SEM (n = 3–4; **P5 0.01). ns = not significant.
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Figure 2 Experimental design and expression of transgenes. (A and B) Experimental design. Wild-type mice between 21–25 days of age
(P21–25) were co-injected in the cerebellar vermis with lentiviral vectors (LV) encoding full-length mutant ataxin 3 with 72 glutamine
repeats (Atx3Q72) along with beclin 1 or GFP (control) (A). Transgenic mice expressing a fragment of mutant ataxin 3 truncated upstream
the 69 glutamine repeats (Tg-Q69), 21–25 days old (P21–25) were injected in the cerebellar vermis with lentiviral vectors encoding beclin
1 or GFP (control) (B). For both models, motor behavioural testing started 1 day before lentiviral-injection (T0) up to 10 weeks post-
injection. At that time point, mice were sacrificed and processed for histological analysis. (C–F) Cresyl violet staining. Cresyl violet staining
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mice (LV-Atx3Q72 + control), observed at 10 weeks post-injection
(Fig. 3A; n = 7; 120.93  8.07 versus 81.08  4.02 in control,
*P50.05). Importantly at this time-point, the Rotarod perform-
ance of beclin 1-treated LV-Atx3Q72 was indistinguishable from
non-injected wild-type mice (Fig. 3A; n = 7–8; 120.93  8.07
versus 120.25  12.60 in wild-type), suggesting a total rescue re-
garding this test. The Tg-Q69 mouse model showed dramatic
motor impairments since the beginning of the test when compared
with wild-type mice (Fig. 3B; T0: 17.88  2.32 versus
120.05  6.60 in wild-type, P50.001), nevertheless beclin 1
was able to improve the performance of the mice along time,
reaching statistical significance at 10 weeks post-injection
(Fig. 3B; n = 8; 40.28  9.35 versus 13.95  3.07 in control,
P5 0.05). Nevertheless, at that time point the performance of
the beclin 1-treated transgenic mice continued to be substantially
lower as compared with wild-type. Therefore, to further assess the
balance and motor coordination of transgenic mice, the beam test
was used. Beclin 1 was able to preserve along time the ability of
Tg-Q69 mice to walk or grip the most difficult beams (0.5 and
0.8 cm round) without falling; when compared to control-treated,
a significant improvement was observed from 2 weeks post-injec-
tion (Fig. 3D; n = 8; T2: 0.54  0.038 versus 0.71  0.067 in con-
trol, P50.05; T10: 0.54  0.038 versus 0.73  0.049 in control,
P5 0.01). In this test, beclin 1-treated transgenic mice showed no
statistical difference from non-injected wild-type mice. No differ-
ences were observed in the LV-Atx3Q72 model and wild-type
(Fig. 3C) as this model had a mild phenotype compared with
the transgenic model.
Altogether, these results show that beclin 1 overexpression
when initiated at the same time as induction of pathology (LV-
Atx3Q72) is able to completely rescue the motor coordination and
balance skills, while a partial rescue is achieved upon intervention
at a late stage of the disease (Tg-Q69).
Beclin 1 hampers the development and
progression of ataxic phenotype
An important characteristic of Machado–Joseph disease, as well as
of other SCAs and/or polyglutamine diseases is the development
of gait and limb ataxia (Carter et al., 1999; Goti et al., 2004; Chen
et al., 2008). For that reason, we next analysed footprint patterns
to evaluate whether beclin 1 was able to delay the appearance of
the ataxic phenotype in the LV-Atx3Q72 (Fig. 4A, C, E and G)
and Tg-Q69 model (Fig. 4B, D, F and H). Strikingly, at the 10
week time-point beclin 1-treated LV-Atx3Q72 mice were indistin-
guishable from wild-type mice regarding stride length (Fig. 4A;
n = 8; T10: 7.36  0.18 versus 6.30  0.13 in control,
P50.001), front base width (Fig. 4C; n = 8; T10: 1.30  0.07
versus 1.54  0.03, P5 0.01), hind base width (Fig. 4E; n = 8;
T10: P40.05) and distance between front and hind limb overlap
in consecutive footsteps (Fig. 4G; n = 8; T10: 0.68  0.07 versus
1.00  0.09, P50.05). In the opposite, control GFP-treated LV-
Atx3Q72 mice exhibited significant impairments in all parameters,
displaying shorter stride length, wider front base width and
increased distance in the footprint overlap.
Surprisingly, already at T0 the Tg-Q69 mice were phenotypically
distinct from the wild-type regarding gait (reaching statistical dif-
ference on the stride length, Fig. 4B), beclin 1 was able to signifi-
cantly increase the stride length (Fig. 4B, n = 8; 6.50  0.26 versus
5.56  0.21 in control, P50.01) and decrease the distance be-
tween front and hind limb overlap (Fig. 4H, n = 8; 0.73  0.07
versus 1.17  0.16 in control, P5 0.05) at 10 weeks post-injec-
tion. No significant differences were reached regarding the front
base width (Fig. 4D) and hind base width (Fig. 4F) even though
beclin 1 mediated a slight tendency for improvement. Importantly,
at that time-point beclin 1-expressing Tg-Q69 mice were not stat-
istically different from wild-type concerning the footprint overlap
measurement (Fig. 4H). These results show that beclin 1 is able
not only to hamper the development of an ataxic gait when ex-
pressed before onset of disease (LV-Atx3Q72), but also to medi-
ate a partial rescue when administered after onset of symptoms in
a severe-progressive model of polyglutamine disease/SCA (Tg-
Q69).
Beclin 1 decreases aggregation of
polyglutamine–expanded ataxin 3
Machado-Joseph disease as well as the other polyglutamine dis-
eases is characterized by the presence of insoluble aggregates of
expanded protein, in this case of ataxin 3 (Paulson et al., 1997). In
previous work we showed that beclin 1 was able to increase the
autophagic flux, consequently leading to an improved clearance of
mutant ataxin 3 protein and decrease the number of mutant ag-
gregates present in the rat striatum (Nascimento-Ferreira et al.,
Figure 2 Continued
of the lentiviral (C and E) and transgenic model (D and F) at the moment of injection (P21). E and F are high-magnifications of C and D,
respectively. Note the cerebellar atrophy present in the transgenic mice at the level of the molecular layer (F, arrows) as compared to the
lentiviral mouse model (E, arrows) already at 21 days of age. (G and H) In vivo expression of the transgene. Direct fluorescence of GFP
expression at 10 weeks post-injection after a single lentiviral injection in the cerebellar vermis of the lentiviral (G) and transgenic mouse
model (H). Scale bar: 200mm. (I and K) Western blot analysis of mice injected with Atx3Q72 plus beclin 1 or control, showing beclin 1
expression (bec) in the cerebellar lysates 2 weeks post-infection (I). Quantification by optical densitometry revealed a significant increase
of beclin 1 levels (K) Actin was used as loading control and results are expressed as ratio beclin 1/actin. Values are expressed as
mean  SEM (n = 3; *P50.05). (J and L) Western blot analysis of cerebellar cortex primary cultures derived from Tg-Q69 mice at 7 days
of age (P7). Cultures were infected with lenviral vectors enconding GFP (control) or beclin 1 transgene and analysed 2 weeks post-
infection (J). Quantification by optical densitometry revealed a significant increase of beclin 1 levels (L). Actin was used as loading control
and results are expressed as ratio beclin 1/actin. Values are expressed as mean  SEM (n = 3; **P5 0.01). ML = molecular layer;
GL = granular layer.
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2011). Therefore in the present work we investigated if beclin 1
would clear mutant ataxin 3 aggregates formed in the cerebellum
of LV-Atx3Q72 and Tg-Q69 mice (Fig. 5). Because the aggregates
formed by both of these models had been previously characterized
(Torashima et al., 2008; Nobrega et al., 2012) here we only
focused on the clearance quantification of ataxin 3 aggregates
stained with the 1H9 antibody (Fig. 5A–C) and haemagglutinin
(Fig. 5D–H). In the LV-Atx3Q72 model, at 10 weeks
post-injection, beclin 1 mediated a robust clearance of mutant
ataxin 3 aggregates relative to controls (Fig. 5A–C; 1H9 immunos-
taining; n = 6; 282.6  57.92 versus 926.3  172.5 in control,
P = 0.0054). Interestingly, at that same time-point the pattern of
truncated ataxin 3 staining in Tg-Q69 mice was mainly diffuse
with very few aggregates (Fig. 5D–H; haemagglutinin tag immu-
nostaining). When present, aggregates were mainly present in the
Purkinje cells of control-injected mice (Fig. 5D and F) (Fig. 5H;
Accelerated rotarod
BA
Beam test
DC
Figure 3 Beclin–1 improves balance and motor coordination deficits in lentiviral based and transgenic mouse models of polyglutamine
disease. (A and B) Accelerated Rotarod test. Mice were forced to walk on accelerated rotarod apparatus (4–40 rpm in 5 min). Latency to
fall was measured for each time point for the LV-Atx3Q72 model (A) and Tg-Q69 model (B). Beclin 1 administration significantly
improved the motor performance of LV-Atx3Q72 mice (A) when compared to GFP/control at 10 weeks post-injection. Note that at this
time point beclin 1-treated mice were not statistically different from non-injected wild-type (WT) mice. Overexpression of beclin 1 in Tg-
Q69 (B) led to improvement of motor coordination and balance along time, specially at 10 weeks post-injection. Note that the motor
performance of these mice was significantly different from non-injected wild-type from the beginning of the study (T0). Results are
expressed as mean  SEM (n = 8; *P50.05; ***P50.001). (C and D) Modified beam test. The ability to hold for 15 s in a cylindrical 0.5
and 0.8 cm as well as 1 cm square beam was accessed in the lentiviral (C) and transgenic model (D). The score number reveals the beam in
which mice were able to perform the test. No differences were observed between the lentiviral model and wild-type mice regarding this
test (C). On the other hand control-treated Tg-Q69 mice showed lower performances when performing this test when compared to beclin
1-injected or non-injected wild-type mice already at 2 weeks post-injection (D). Note that beclin 1- treated mice are not statistically
different from non-injected wild-type. Values are expressed as mean  SEM (n = 8; *P50.05; **P50.01; ***P50.001).
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Figure 4 Beclin–1 improves the ataxic phenotype when administered before and after onset of the disease. (A–H) Footprint pattern
quantitative analysis. (A and B) Stride length relative to hind paw of LV-Atx3Q72 (A) and of Tg-Q69 model (B). Analyses show that beclin
1-treated mice have a longer stride length. Values are expressed as mean  SEM (n = 8; **P5 0.01; ***P50.001; n.s. = no significant
difference). (C and D) Front base width of LV-Atx3Q72 (C) and of Tg-Q69 model (D). Beclin 1-treated mice have a narrower front base
width compared to control-treated mice. Values are expressed as mean  SEM (n = 8; **P50.01; ***P50.001). (E and F) Hind base
width of LV-Atx3Q72 (E) and of Tg-Q69 model (F). No statistical differences were observed between the LV model and wild-type (E) and
no statistical differences were observed between control and beclin 1-treated Tg mice (F). Values are expressed as mean  SEM (n = 8;
*P5 0.05; n.s. = no significant difference). (G and H) Distance between the placement of hind and front paw in consecutive steps or
footprint overlap. In both models beclin 1-treated mice are statistically different from control-treated and no different from wild-type mice
regarding the distance of footprint overlap. Values are expressed as mean  SEM (n = 8; *P50.05; **P50.01; ***P50.001).
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n = 4-5; 25.17  2.275 versus 15.89  2.241 in beclin 1-treated,
P = 0.0244). These data show that beclin 1 expression decreases
the level of polyglutamine-expanded ataxin 3 aggregates.
Beclin 1 prevents neuronal dysfunction
and neurodegeneration
To investigate whether impairments in motor function would
correlate with histological changes in the cerebellum, we next
examined the immunoreactivity for the dopamine- and cyclic
AMP-regulated phosphoprotein of 32 KDa/DARPP-32 (now
known as Ppp1r1b) and calbindin protein within the molecular
and Purkinje cell layers. Both markers were present in Purkinje
cell’s bodies and dendrites with similar staining patterns.
Importantly, in the control-treated LV-Atx3Q72 model (Fig. 6A),
reduced dendritic arborizations of the Purkinje cells and decreased
immunoreactivity for DARPP-32 at the level of Purkinje cells and
dendrites were observed, compared with beclin 1-treated mice
(Fig. 6B) and wild-type (Fig. 6C). By quantifying the DARPP-32
immunoreactivity by optical densitometry (Fig. 6G) we observed
that not only beclin 1-treated mice had an increased immunoreac-
tivity for DARPP-32 compared with control-treated, but also were
very similar to wild-type mice (Fig. 6G; n = 6; 3.02  0.21 in con-
trol versus 6.96  1.24 in beclin 1-treated; P50.05; wild-type:
7.76  1.05). Similar findings were observed using the calbindin
marker (Fig. 6D–F and H). In addition, no differences were
observed in the molecular layer thickness in this model when
compared with wild-type mice (Fig. 6I), which indicates that cere-
bellar atrophy was not present in this model at this 10 weeks time-
point.
To further examine morphological abnormalities between beclin
1 and control-treated LV-Atx3Q72 mice, a cresyl violet staining
was performed (Fig. 6J–N). Beclin 1-injected mice revealed a pre-
served cellular morphology (Fig. 6K and M) as compared with
control-treated mice (Fig. 6J and L), where several vacuoles
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Figure 5 Beclin–1 alters the aggregation pattern. (A–C) Fluorescence microscopy analysis of mutant ataxin 3 aggregates in the lentiviral-
based model (LV-Atx3Q72) revealed by the 1H9 antibody at 10 weeks post-injection. Aggregates were mainly present in the molecular
and Purkinje cell layer of the cerebellar cortex and rarely seen in the granular layer. Scale bar = 20 mm. Quantification of mean number of
aggregates per section revealed a beclin 1-mediated reduction of the number of aggregates as compared to control (C). Values are
expressed as mean  SEM (n = 6; **P50.01). (D–H) Fluorescence microscopy analysis of haemagglutinin (HA)-tagged truncated ataxin
3 protein in the transgenic model (Tg-Q69) at 10 weeks post-injection. Immunohistochemistry for haemagglutinin antibody revealed a
predominantly diffuse expression of the mutant ataxin 3 protein. Aggregates were present occasionally mainly in Purkinje cells of the
control-injected mice (D and F, arrows). Scale bar = 20 mm. Quantification of mean number of aggregates per 100 cells revealed a beclin
1-mediated reduction of the number of aggregates as compared to control (H). Values are expressed as mean  SEM (n = 4–5;
*P5 0.05).
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Figure 6 Beclin–1 protects from neuronal dysfunction. (A–C) Fluorescence microscopy analysis for the DARPP-32 protein in the lentiviral
model (LV-Atx3Q72) and wild-type mice (WT). Immunohistochemistry for the DARPP-32 protein highlighted the Purkinje cells and their
dendritic projection to the molecular layer. An increased expression of DARPP-32 neuronal marker was observed for the beclin 1-treated
mice (B) relative to control-treated (A). Scale bar = 20 mm. (G) Quantification of optical densitometry of DARPP-32 immunoreactivity.
Beclin 1 significantly increased DARPP-32 expression as compared to control. Note that beclin 1-injected mice are not statistically different
than wild-type mice regarding the DARPP-32 immunoreactivity. Values are expressed as mean  SEM (n = 6; *P50.05; n.s = no
significant difference). (D–F) Fluorescence microscopy analysis for calbindin protein in the lentiviral model (LV-Atx3Q72) and wild-type
mice (WT). An increased expression of calbindin marker was observed for the beclin 1-treated mice (E) relative to control-treated (D).
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were present in the granular and Purkinje cell layer. By quantifying
the number of Purkinje cells per length unit, we observed a
decreased cell number in the control-treated as compared to
beclin-1 treated mice (Fig. 6N; n = 4; 4.00  0.15 versus
2.67  0.19 in control; P50.01).
Next, by analysing the Tg-Q69 model with the calbindin
(Fig. 7A–C and J), DARPP-32 (Fig. 7D–F and K) and cresyl
violet marker (Fig. 7G–I and L) we observed that beclin 1 over-
expression mediated preservation of Purkinje cell morphology
(Fig. 7B), dendritic arborizations (Fig. 7B, ML) and calbindin immu-
noreactivity (Fig. 7J) as compared with control-treated mice
(Fig. 7A and J). No major differences were observed with the
DARPP-32 staining (Fig. 7D–F and K). Interestingly, severe atro-
phy of the molecular layer of the cerebellum was apparent in this
model as compared to wild-type mice (Fig. 7A–C and G–I,
arrows), which was partially prevented by beclin 1 administration
(Fig. 7B and H). Quantification of the molecular layer thickness
confirmed that cerebellar atrophy was present in this model
(Fig. 7L; n = 7; 23.34–29.86 mm in Tg-Q69 versus 156.5–
164.7 mm in wild-type), which was hindered by beclin 1 overex-
pression (Fig. 7L; n = 7; 28.87  0.99 in beclin 1-treated versus
24.30  0.96 in control-treated mice; P5 0.01). In summary,
these data show that beclin 1 prevents neuronal dysfunction and
neurodegeneration, in agreement with the improvements
observed in motor function.
Discussion
Using both a presymptomatic lentiviral model and a severely af-
fected transgenic mice modelling Machado–Joseph disease, we
provide evidence that beclin 1 overexpression is able to prevent
or partially rescue motor impairments characteristic of this
disorder.
The simultaneous overexpression of beclin 1 and induction of
Machado–Joseph disease (lentiviral-based model) was able to
hamper the disease progression regarding balance, motor coord-
ination and gait performances. After 10 weeks of beclin 1 over-
expression, lentiviral-based Machado–Joseph disease mice
(Nobrega et al., 2012) were indistinguishable from wild-type
mice regarding the motor phenotype. These results are in agree-
ment to previous reports in conditional mouse models of different
polyglutamine diseases (Yamamoto et al., 2000; Zu et al., 2004;
Boy et al., 2009). In these conditional mouse models the revers-
ibility of the pathology was achieved by switching off the mutant
protein transgene in an early stage of disease. In the present
study, the mutant ataxin 3 transgene was continuously expressed,
mimicking a more realistic scenario. This indicates that neural cells
are capable of overcoming the pathology progression if protein
clearance mechanisms remain functional.
Protein clearance mechanisms are particularly important for
neurons, which can not eliminate their abnormal proteins or
other toxic species by cell division (Cuervo, 2004; Wong and
Cuervo, 2010). As insoluble polyglutamine inclusions are scarcely
removed by the ubiquitin-proteasome system, which may become
progressively impaired in these diseases (Bence et al., 2001;
Venkatraman et al., 2004), autophagy is most probably respon-
sible for the ability of these cells to clear mutant proteins and
reverse the pathology after switching- off of the transgene in
conditional disease models. Autophagy has been shown to play
a central role in misfolded protein clearance within the CNS, par-
ticularly in diseases caused by insoluble and aggregation-prone
proteins, such as Alzheimer’s disease, Parkinson’s disease and
polyglutamine diseases (Ravikumar et al., 2004; Pickford et al.,
2008; Spencer et al., 2009). In a previous study, we observed
that autophagy was impaired in Machado–Joseph disease and
beclin 1 levels decreased, whereas overexpression of beclin 1 sti-
mulated the autophagy pathway, cleared misfolded ataxin 3 pro-
tein and protein aggregates while promoting neuroprotection,
observed at the histological level.
Here, our main focus was to investigate beclin 1 effects on
motor behaviour. Beclin 1-mediated neuroprotective effects were
dependent on the timing of intervention and disease status. When
administered to a transgenic mouse model with severe cerebellar
atrophy and ataxic phenotype (Torashima et al., 2008), the
observed effects, within the 10 week time-frame of the study,
were relatively modest considering the results obtained with the
lentiviral-based Machado–Joseph disease mice (Nobrega et al.,
2012), which were indistinguishable from normal wild-type mice
for most of the parameters studied. Nevertheless, beclin 1-over-
expression in the transgenic mice mimicking a late stage of disease
at the moment of viral injection in the cerebellum, led to a partial
rescue of the phenotype, at the balance, motor coordination and
gait levels. In addition, even though lentiviral vectors efficiently
transduce Purkinje cells, cells targeted by the truncated ataxin 3
vector driven by the L7-promoter in this transgenic model, not all
cells can be transduced by lentiviral vectors and therefore we can
not exclude an insufficient beclin 1 expression within the whole
cerebellum. Moreover, the duration of the study was the same
used for the lentiviral-based model (10 weeks), which may not
have been sufficient to maximize the therapeutic effects in the
transgenic model. Therefore, beclin 1 effects on a middle stage
of polyglutamine ataxia and in a late stage during longer periods
Figure 6 Continued
Scale bar = 20 mm. (H) Quantification of optical densitometry of calbindin immunoreactivity. Beclin 1 significantly increased calbindin
expression as compared to control. Values are expressed as mean  SEM (n = 4; *P5 0.05; n.s. = no significant difference). (I)
Quantification of the width of the molecular layer of the cerebellum by the DARPP-32 staining. No significant differences were observed
between the lentiviral-based model and wild-type mice. (J–N) Cresyl violet analysis in the lentiviral-based model. Cresyl violet staining in
beclin 1-treated mice (K and M) highlighted a better cellular morphology and cell number as compared to control-treated mice (J and L). In
the control-treated LV-Atx3Q72 mice (J and L) a vacuolar pattern were present in the granular and Purkinje cell layer. Scale bar = 200 mm
(J and K) and 40 mm (L and M). (N) Quantification of the Purkinje cell number. Beclin 1 overexpression protected mice from cell loss.
Results are expressed as mean  SEM (n = 4; **P50.001). ML = molecular layer; PCL = Purkinje cell layer; GL = granular layer.
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Figure 7 Beclin–1 protects against cerebellar atrophy. (A–C) Fluorescence microscopy analysis for the calbindin protein, in transgenic (A
and B) and wild-type mice (C). Note the improved Purkinje cell morphology (B, PCL) and dendritic arborizations to the molecular layer (B,
arrows) upon beclin 1 overexpression as compared to control (A). Scale bar = 40 mm. ML = molecular layer; PCL = Purkinje cell layer;
GL = granular layer. (J) Quantification of optical densitometry of calbindin immunoreactivity. Beclin 1 significantly increased calbindin
expression as compared to control, reaching similar values to wild-type mice. Values are expressed as mean  SEM (n = 4; *P5 0.05;
n.s. = no significant difference). (D–F) Fluorescence microscopy analysis for the DARPP-32 protein, in transgenic (D and E) and wild-type
mice (F). (K) Quantification of optical densitometry of DARPP-32 immunoreactivity. No differences were observed between beclin 1 and
control for this marker. Values are expressed as mean  SEM (n = 3; *P50.05; **P50.01; n.s = no significant difference). (G–I) Cresyl
violet staining. Note the reduced molecular layer width of the transgenic model (G and H, arrows) as compared to wild-type mice (I,
arrows). Nevertheless, an increased width of the molecular layer in beclin 1-treated mice (H, arrows) relative to control-treated (G, arrows)
was observed. Scale bar = 40 mm. (L) Quantification of the width of the molecular layer of the cerebellum by the calbindin staining. A
significant increased molecular layer width was observed in the Tg-Q69 mice upon beclin 1 overexpression. Values are expressed as
mean  SEM (n = 7; **P50.001).
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of time remain to be investigated. Nevertheless, the results pre-
sented here are in agreement with the study involving a condi-
tional mouse model of SCA1 (Zu et al., 2004), where complete
reversibility of the disease was achieved by switching off the trans-
gene in early and middle stages of disease, whereas the switching
off in a severe stage improved the phenotype to a middle stage of
disease.
Regarding neuropathology, in accordance with the motor be-
haviour we observed that an early beclin 1 expression was able to
protect neuronal cells and impede the development of neuropath-
ology evaluated by the number of cells with aggregates, DARPP-
32 and calbindin immunoreactivity and number of Purkinje cells,
whereas a ‘late’ administration could ameliorate the neuropathol-
ogy but not completely prevent the cell damage, especially as
when beclin 1 was administered to the transgenic mouse model,
cerebellar atrophy had already taken place. Importantly, beclin 1
expression in the transgenic model was able to preserve Purkinje
cell dendritic arborizations and the width of the molecular layer
of cerebellar cortex, which was substantially decreased in control-
treated compared with wild-type mice, indicative of cerebellar at-
rophy. The fact that beclin 1 was able to decrease the progression
of cerebellar atrophy, revealed by the increased molecular layer
width of treated animals is of major importance and indicative that
even in a late stage of disease and despite the continuous expres-
sion of mutant transgene, it is possible to slow-down the progres-
sion of neurodegeneration and cell death.
The overall results obtained with beclin 1 overexpression in the
lentiviral-based and transgenic mouse model relative to motor
function and Purkinje cell pathology show a correlation between
neuropathology and motor behaviour. Moreover these results in-
dicate that Purkinje neurons retain the ability to recover from
polyglutamine-expanded ataxin 3-induced toxicity, being able to
improve complex motor skills such as motor coordination, balance
and gait.
This work, despite overall supporting an early intervention for
Machado-Joseph disease and polyglutamine diseases, shows that
rescue of the pathology is also possible in advanced stages, at
least partially, by upregulating beclin 1 levels. This effect was
observed both for full-length and truncated mutant ataxin 3 and
may also benefit other polyglutamine diseases.
Machado–Joseph disease as well as other polyglutamine dis-
eases is a genetic hereditary disease with known aetiology.
Presently, genetic testing to diagnose Machado–Joseph disease
can be performed pre-implantation, in uterus or after birth. This
indicates that once available, a therapeutic treatment can be
initiated before onset of symptoms. In this regard, the knowledge
that upregulation of beclin 1 is able to clear the initial disease-
causing mutant ataxin 3 protein and delay the progression of
motor impairments may be of major importance. Moreover, it
has been recently shown that some drugs upregulate beclin 1
(Can et al., 2011; Huang et al., 2011), introducing new thera-
peutic value for these drugs and hopefully for several neurode-
generative diseases. Unfortunately, given that these drugs may
account for several secondary effects, no perfect drug or treat-
ment is for the moment available for Machado–Joseph disease.
Altogether this study shows that overexpression of beclin 1 is
able to prevent the polyglutamine-related behaviour and
neuropathology, when administered to an early stage and to par-
tially hamper the progression of the pathological phenotype when
administered to a late stage of the disease. As beclin 1 has been
found to be decreased in neurodegenerative diseases; upregulation
of beclin 1, genetically or pharmacologically may represent a pro-
mising therapeutic approach for polyglutamine diseases and over-
all to neurodegenerative diseases.
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